View in EDS

Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan.

Saved in:
Bibliographic Details
Title: Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Colorectal Cancer With High Microsatellite Instability or Mismatched Repair Deficiency in Japan.
Authors: Taniguchi S; Division of Health Policy and Management, Department of Biomedical Science, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan., Moriwaki K; Division of Health Policy and Management, Department of Biomedical Science, College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan University, Kyoto, Japan. Electronic address: moriken820318@gmail.com., Morimoto K; Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan University, Kyoto, Japan., Shimozuma K; Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology, Ritsumeikan University, Kyoto, Japan.
Source: Value in health regional issues [Value Health Reg Issues] 2025 Dec 10; Vol. 54, pp. 101555. Date of Electronic Publication: 2025 Dec 10.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101592642 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-1102 (Electronic) Linking ISSN: 22121099 NLM ISO Abbreviation: Value Health Reg Issues Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2212-1102
DOI:10.1016/j.vhri.2025.101555